PressReleases
Press Releases
Kineta Press Releases
SEATTLE, May 24, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel
SEATTLE, May 23, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel
Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout
SEATTLE, April 24, 2023 — Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
SEATTLE, April 20, 2023 — Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on
SEATTLE, April 17, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel
VISTA blocking immunotherapy engineered to address immunosuppression in the tumor microenvironment (TME) Phase 1 initial data readout anticipated by
SEATTLE, April 03, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies
Opened a Phase 1/2 clinical study of VISTA Targeting KVA12123 for Advanced Solid Tumors Initial Data Readout Anticipated by
Disclaimer: The Press Releases on this page are provided for historical purposes only. The information contained in each [press release/news article/event] is accurate only as of the date each was originally issued. Kineta disavows any obligation to update the information after the date of their issuance.